NEW YORK (GenomeWeb) – Epigenomics said today that it will receive a two-year, €2.8 million ($3.1 million) EU grant to fund clinical research to validate the company's lung cancer biomarkers.

The grant will be administered through the Industrial Leadership pillar of the EU's Horizon 2020 Research and Innovation Program for Small and Medium Enterprise Businesses.

The ultimate goal of Epigenomics' project is to develop a CE-marked product to detect lung cancer in blood plasma, the company said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

British Nobel laureates and Fields Medal winners warn that a 'hard' Brexit could harm science across the UK, the Guardian reports.

Vox reports on inequities in genetic research and efforts to address them.

The New York Times reports that Arizona State University's Lawrence Krauss is retiring following allegations of sexual misconduct.

In PNAS this week: de novo NUS1 mutations linked to Parkinson's disease risk, candidate hepatocellular carcinoma drivers, and more.